This Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $324,998 to Minutia Inc., a minority-owned, woman-owned, and Black American-owned for-profit organization, to develop advanced stem cell-derived pancreatic islet cell technologies. The key products or services to be delivered include:
-
Assessing the effect of the TET2 gene deficiency on rendering stem cell-derived islet cells more resilient to inflammatory stress and immune rejection, to improve the efficacy of cell replacement therapy for type 1 diabetes.
-
Leveraging Minutia's proprietary nanosensor technology to enable non-invasive real-time monitoring of the implanted stem cell-derived islet cell grafts, allowing early detection of inflammation or rejection to enable timely intervention.
This research aims to overcome key challenges in stem cell-based pancreatic islet cell replacement therapy, a promising approach to potentially provide a functional cure for type 1 diabetes by restoring normal glucose metabolism and reducing the burden of insulin management.
Generated 3/4/25, 7:07 AM